Dual atrioventricular valve regurgitation (DAVR) significantly reduced 3-year survival to 47.3% compared to isolated MR (64.3%) and TR (54.4%), with HR 1.36 for 3-year mortality.
Does dual atrioventricular valve regurgitation worsen 3-year survival in patients undergoing TAVR?
Dual atrioventricular valve regurgitation is a high-risk condition in TAVR patients, independently predicting increased 3-year mortality.
Absolute Event Rate: 0% vs 0%
Abstract Aims Current guidelines provide no recommendations for the management of patients with dual atrioventricular valve regurgitation (DAVR) undergoing transcatheter aortic valve replacement (TAVR), and existing data on its clinical impact remain absent. Therefore, we aimed to provide detailed insights into the impact of DAVR on outcomes after TAVR, with the potential to refine clinical risk stratification tools and influence future management guidelines. Methods and results We retrospectively analysed 3491 consecutive patients who underwent TAVR between 2013 and 2021. DAVR was defined as the presence of both mitral regurgitation (MR) and tricuspid regurgitation (TR) ≥ 2+. Patients were divided into four groups based on echocardiography before TAVR: no/mild atrioventricular (AV) regurgitation, isolated MR ≥ 2+, isolated TR ≥ 2+, and DAVR. DAVR was present in 269 patients (7.7%) and was associated with significantly reduced 3-year survival (47.3%) compared with isolated MR (64.3%), isolated TR (54.4%), and no/mild AV regurgitation (73.0%, P 0.001). Multivariate analysis identified DAVR as an independent predictor of 3-year mortality hazard ratio (HR): 1.36, 95% confidence interval (CI), 1.1–1.8, P = 0.021. A leading TR ≥ 3+ in DAVR patients was associated with a particularly poor prognosis (3-year survival: 27%). While an MR improvement following TAVR was linked to better survival (HR: 0.45, 95% CI, 0.30–0.69, P 0.001), a TR improvement had no significant impact on survival (HR: 0.69, 95% CI: 0.45–1.05, P = 0.086). Notably, 54% of DAVR patients continued to experience significant exertional dyspnoea at follow-up (NYHA ≥ II). Conclusion These findings underscore the importance of recognizing DAVR as a high-risk condition in TAVR patients, highlighting the need for refined risk stratification tools and potential adjunctive therapeutic strategies to improve outcomes.
Doldi et al. (Fri,) reported a other. Dual atrioventricular valve regurgitation (DAVR) significantly reduced 3-year survival to 47.3% compared to isolated MR (64.3%) and TR (54.4%), with HR 1.36 for 3-year mortality.